Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15031 | 0.78 | CALM1 (0.32) | — | |
| SCHEMBL5852719 | 0.78 | HSPA5 (0.60) | HSPA5KEAP1TSHRCYP2D6HIF1A | |
| SCHEMBL4599279 | 0.77 | GABRA1 (0.57) | HSPA5TSHR | |
| SCHEMBL972443 | 0.77 | TRPA1 (0.44) | HSPA5KEAP1KDM4EHSD17B10 | |
| SCHEMBL10396737 | 0.76 | — | — | |
| SCHEMBL1345567 | 0.76 | IDO1 (0.43) | CYP2D6TAAR1IDO1 | |
| SCHEMBL3237939 | 0.76 | TAAR1 (0.41) | TSHRTAAR1 | |
| SCHEMBL16654780 | 0.76 | CYP3A4 (0.40) | — | |
| SCHEMBL2871136 | 0.76 | TAAR1 (0.42) | TAAR1IDO1KDM4E | |
| SCHEMBL29357407 | 0.75 | HSPA5 (1.00) | HSPA5KEAP1TSHRCYP2D6HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46830-E1 | Method for solid phase peptide synthesis | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2018-05-08 | — | — | US | disclosed |
| US-20170283478-A1 | PROCESS FOR PREPARATION OF LIRAGLUTIDE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-10-05 | — | — | US | disclosed |
| WO-2016005960-A1 | PROCESS FOR PREPARATION OF LIRAGLUTIDE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2016-01-14 | — | — | WO | disclosed |
| US-9040480-B2 | Synthesis of glucagon-like peptide | LONZA AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20130324699-A1 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDE | LONZA AG (CH) | 2013-12-05 | — | — | US | disclosed |
| US-8445433-B2 | Synthesis of glucagon-like peptide | LONZA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-7939629-B2 | Method for solid phase peptide synthesis | LONZA AG (CH) | 2011-05-10 | — | — | US | disclosed |
| EP-1987052-B1 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDES | LONZA AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-20090292106-A1 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDE | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2009-11-26 | — | — | US | disclosed |
| US-20080287648-A1 | Method for Solid Phase Peptide Synthesis | LONZA AG (CH) | 2008-11-20 | — | — | US | disclosed |
| WO-2007090496-A1 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDE | LONZA AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| EP-1794180-A1 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| EP-1737889-A1 | METHOD FOR SOLID PHASE PEPTIDE SYNTHESIS | LONZA AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006032457-A9 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006045503-A1 | METHOD FOR SOLID PHASE PEPTIDE SYNTHESIS | LONZA AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006032457-A1 | PEPTIDE CYCLISATION | LONZA AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0051023-A1 | Derivatives of the benzoyl and alpha hydroxybenzyl-phenyl osides family, method for their preparation and their therapeutic application | SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: (FR) | 1982-05-05 | — | — | EP | disclosed |
| US-4107137-A | Phenolic antioxidants for synthetic polymers | SOCIETE FRANCAISE D'ORGANO SYNTHESE (FR) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292106-A1 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GIPR | HSPA5 1507/4885KEAP1 2734/4885TSHR 293/4885 |
| US-20080287648-A1 | Method for Solid Phase Peptide Synthesis | HM13, VIP, HIRA | HSPA5 1293/4885KEAP1 2627/4885TSHR 1224/4885 |
| US-20130324699-A1 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GIPR | HSPA5 1507/4885KEAP1 2734/4885TSHR 293/4885 |
| US-20170283478-A1 | PROCESS FOR PREPARATION OF LIRAGLUTIDE | GLP1R, IAPP, GCG | HSPA5 1519/4885KEAP1 3840/4885TSHR 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.